Nasdaq Grants XTL Biopharmaceuticals Conditional Listing Extension, Averting Delisting

summarizeSummary

XTL Biopharmaceuticals received a conditional extension from Nasdaq to maintain its listing, contingent on completing the Psyga Bio acquisition and meeting all listing requirements by June 30, 2026.

check_boxKey Events

• Nasdaq Grants Conditional Listing Exception

  The Nasdaq Hearings Panel has determined to grant XTL Biopharmaceuticals an exception for continued listing on The Nasdaq Stock Market, following a hearing held on April 16, 2026.

• Conditions for Continued Listing

  The company must complete the Psyga Bio acquisition and demonstrate compliance with all Nasdaq continued listing requirements on or prior to June 30, 2026.

• Averts Immediate Delisting Threat

  This decision provides a reprieve from a prior notification on February 27, 2026, where Nasdaq believed the company was a "public shell" and warranted delisting.

• Psyga Acquisition is Critical Factor

  The successful completion of the share purchase agreement for Psyga Bio and securing necessary funding were significant factors in the Panel's willingness to grant the exception, as previously disclosed on April 29, 2026.

auto_awesomeAnalysis

XTL Biopharmaceuticals has received a crucial conditional extension from Nasdaq, averting immediate delisting. This decision follows a prior notification from Nasdaq that the company was considered a "public shell." The Nasdaq Hearings Panel has granted an exception for continued listing, contingent on the company completing its previously announced acquisition of Psyga Bio Ltd. and demonstrating compliance with all Nasdaq listing requirements by June 30, 2026. While this provides a significant reprieve and removes an immediate existential threat, the company still faces substantial execution risk to meet these conditions, particularly the completion of the Psyga Bio transaction, which was a key factor in the Panel's decision. Investors should monitor progress on the acquisition and overall compliance closely.